$4.81
+0.23 (+5.02%)
Open$4.71
Previous Close$4.58
Day High$4.84
Day Low$4.65
52W High$7.75
52W Low$3.71
Volume—
Avg Volume142.8K
Market Cap109.55M
P/E Ratio—
EPS$-1.15
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+666.1% upside
Current
$4.81
$4.81
Target
$36.85
$36.85
$27.29
$36.85 avg
$45.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 10.82M | 21.48M | 20.04M |
| Net Income | -28,894,750 | -5,165,355 | -3,853,498 |
| Profit Margin | -267.1% | -24.1% | -19.2% |
| EBITDA | -30,666,652 | -6,655,427 | -5,995,002 |
| Free Cash Flow | — | -3,535,951 | -2,421,928 |
| Rev Growth | — | -8.7% | +0.8% |
| Debt/Equity | — | 0.24 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |